Replimune Group, Inc. (REPL)
20.06
+0.57
(+2.92%)
USD |
NASDAQ |
Nov 03, 14:14
Replimune Group Enterprise Value : 1.667B for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 1.667B |
| October 30, 2026 | 1.489B |
| October 29, 2026 | 1.468B |
| October 28, 2026 | 1.342B |
| October 27, 2026 | 1.057B |
| October 26, 2026 | 1.002B |
| October 23, 2026 | 905.83M |
| October 22, 2026 | 956.07M |
| October 21, 2026 | 930.48M |
| October 20, 2026 | 902.03M |
| October 19, 2026 | 866.96M |
| October 16, 2026 | 848.94M |
| October 15, 2026 | 933.32M |
| October 14, 2026 | 899.19M |
| October 13, 2026 | 967.45M |
| October 12, 2026 | 1.058B |
| October 09, 2026 | 1.092B |
| October 08, 2026 | 1.056B |
| October 07, 2026 | 1.071B |
| October 06, 2026 | 1.076B |
| October 05, 2026 | 1.066B |
| October 02, 2026 | 1.058B |
| October 01, 2026 | 1.094B |
| September 30, 2026 | 1.075B |
| September 29, 2026 | 1.008B |
| Date | Value |
|---|---|
| September 28, 2026 | 971.43M |
| September 25, 2026 | 954.63M |
| September 24, 2026 | 974.79M |
| September 23, 2026 | 1.005B |
| September 22, 2026 | 1.048B |
| September 21, 2026 | 997.46M |
| September 18, 2026 | 1.014B |
| September 17, 2026 | 997.46M |
| September 16, 2026 | 1.005B |
| September 15, 2026 | 1.011B |
| September 14, 2026 | 1.018B |
| September 11, 2026 | 1.002B |
| September 10, 2026 | 1.029B |
| September 09, 2026 | 1.130B |
| September 08, 2026 | 1.157B |
| September 04, 2026 | 1.180B |
| September 03, 2026 | 1.201B |
| September 02, 2026 | 1.259B |
| September 01, 2026 | 1.233B |
| August 31, 2026 | 1.202B |
| August 28, 2026 | 1.218B |
| August 27, 2026 | 1.227B |
| August 26, 2026 | 1.250B |
| August 25, 2026 | 1.244B |
| August 24, 2026 | 1.152B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kalaris Therapeutics, Inc. | -44.53M |
| Arrowhead Pharmaceuticals, Inc. | 8.182B |
| Oncolytics Biotech, Inc. | 46.19M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.192B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.12M |
| Total Expenses (Quarterly) | 57.12M |
| EPS Diluted (Quarterly) | -0.5431 |
| Earnings Yield | -14.55% |
| Normalized Earnings Yield | -14.55 |